Hftril 200 Tablet is a fixed-dose combination medication containing Sacubitril 97 mg and Valsartan 103 mg, indicated for the treatment of heart failure with reduced ejection fraction (HFrEF). Sacubitril, a neprilysin inhibitor, enhances the levels of natriuretic peptides by preventing their degradation, leading to vasodilation, natriuresis, and diuresis, which collectively reduce cardiac workload and improve cardiac function. Valsartan, an angiotensin II receptor blocker (ARB), inhibits the vasoconstrictive and aldosterone-secreting effects of angiotensin II, thereby lowering blood pressure and decreasing afterload. The synergistic action of these agents results in improved hemodynamics and reduced progression of heart failure. Hftril 200 is typically prescribed to patients who remain symptomatic despite optimal therapy with ACE inhibitors or ARBs alone. Clinical trials have demonstrated that this combination significantly reduces cardiovascular mortality and hospitalization rates in heart failure patients. It is essential to monitor renal function, serum potassium, and blood pressure during therapy to mitigate potential adverse effects such as hypotension, hyperkalemia, and renal impairment. Hftril 200 should be used under strict medical supervision, with dosage adjustments based on individual patient response and tolerability.